| Project/Area Number |
18K16525
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55060:Emergency medicine-related
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | MicroRNA / 骨髄由来抑制細胞 / sepsis / immunosuppression / 遺伝子治療 / 敗血症 |
|---|
| Outline of Final Research Achievements |
In the first year, we evaluated the time course changes of comprehensive microRNA expression by the next-generation sequencing after extraction of blood and peritoneal macrophage of rat sepsis model using lipopolysaccharide injection. Subsequent next year, we have extracted rat myeloid-derived suppressor cell from blood and peritoneal cavity by positive selection of the cell surface marker. Thereafter, we evaluated the time course changes of comprehensive microRNA expression by the next-generation sequencing. Changes in microRNA expression were observed in rat macrophages and myeloid-derived suppressor cells in rats under sepsis compared with rats by saline infusion(control group)
.
|
| Academic Significance and Societal Importance of the Research Achievements |
１つのmiRNAが複数の遺伝子の発現に関与していることから、今まで１つのタンパク質の発現変化で説明が出来なかったCommon Diseaseの病態解明、バイオマーカー、治療薬としてmiRNAの解析は期待できる。報告者らは、敗血症病態時の骨髄由来抑制細胞が産生するmiRNAが重要な役割を担うと考える。
|
